Seattle Genetics officially has the first-line Adcetris nod in advanced classical Hodgkin lymphoma that it’s been gunning for. Now, it’ll be up to the company to capitalize on what CEO Clay Siegall has called “the biggest market opportunity that we have yet looked at.”
The FDA gave Adcetris the go-ahead Tuesday, green-lighting the drug, in tandem with chemo, to treat adults with stage III or IV forms of the disease.
That label is more favorable than at least one analyst predicted; back in December, SunTrust’s Yatin Suneja wrote to clients that Adcetris was “likely to be limited to younger (age <60 years) patients and/or those with Stage IV disease,” restrictions that would have narrowed “the total addressable patient population and hence the market potential of Adcetris,” he said.
It’s also one that Siegall and co. approve of. “I believe that if FDA goes ahead and approves this with a label that says ‘advanced Hodgkin lymphoma,’ I think that that would be very good because it puts it in the doctors’ hands to decide on their patients,” the skipper said in a December interview at the American Society of Hematology annual meeting.
With the approval in hand, Seattle Genetics expects to see Adcetris eventually become a billion-dollar drug in Canada and the U.S. alone—and last year, the company beefed up its sales force by about 30% to prepare for the possibility. At this point, “we think with the U.S. and Canada, we have it covered well,” Siegall said, pointing to “very high market penetration” that he believes bodes well for the new indication.
“We feel very good about how we’ve launched and continue to sell and market Adcetris,” he added.
Patient numbers aren’t huge in Hodgkin lymphoma; only 8,260 U.S. patients were diagnosed with the disease last year, according to the FDA.
But one point in Seattle Genetics’ favor? It won’t have a slew of new competitors to contend with. The new Adcetris approval marks an upgrade to advanced Hodgkin lymphoma treatment regimens that have been around for more than 40 years.